Research ArticleHuman Studies
Randomized Controlled Trial for Hepatocellular Carcinoma with Portal Vein Thrombosis: Intra-arterial Iodine-131-Iodized Oil Versus Medical Support
Jean-Luc Raoul, Dominique Guyader, Jean-François Bretagne, Régis Duvauferrier, Patrick Bourguet, Djemal Bekhechi, Yves M. Deugnier and Michel Gosselin
Journal of Nuclear Medicine November 1994, 35 (11) 1782-1787;
Jean-Luc Raoul
Dominique Guyader
Jean-François Bretagne
Régis Duvauferrier
Patrick Bourguet
Djemal Bekhechi
Yves M. Deugnier
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Randomized Controlled Trial for Hepatocellular Carcinoma with Portal Vein Thrombosis: Intra-arterial Iodine-131-Iodized Oil Versus Medical Support
Jean-Luc Raoul, Dominique Guyader, Jean-François Bretagne, Régis Duvauferrier, Patrick Bourguet, Djemal Bekhechi, Yves M. Deugnier, Michel Gosselin
Journal of Nuclear Medicine Nov 1994, 35 (11) 1782-1787;
Randomized Controlled Trial for Hepatocellular Carcinoma with Portal Vein Thrombosis: Intra-arterial Iodine-131-Iodized Oil Versus Medical Support
Jean-Luc Raoul, Dominique Guyader, Jean-François Bretagne, Régis Duvauferrier, Patrick Bourguet, Djemal Bekhechi, Yves M. Deugnier, Michel Gosselin
Journal of Nuclear Medicine Nov 1994, 35 (11) 1782-1787;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis
- Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?
- Transarterial Injection of 131I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer
- Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up
- Hepatocellular Carcinoma: The Need for Progress
- Molecular Prediction of Response to 5-Fluorouracil and Interferon-{alpha} Combination Chemotherapy in Advanced Hepatocellular Carcinoma